Regulatory Health Canada approves Biocon’s two denosumab biosimilars Pharmaceutical TechnologyBiocon has received a Notice of Compliance from Health Canada for Bosaya and Vevzuo, both biosimilars referencing Prolia and Xgeva, respectively.RegulatoryRead full story pharminent April 22, 2026 (Last updated: April 22, 2026) Pharmaceutical Technology Biocon has received a Notice of Compliance from Health Canada for Bosaya and Vevzuo, both biosimilars referencing Prolia and Xgeva, respectively. RegulatoryRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Tortugas debuts with $106M and brain drugs from Hansoh, EisaiNext: Medicare obesity drug pilot extended after insurer pushback Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
